Sachin Pai

Assistant Professor

University of South Alabama
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Supplemental Figure 1. Key Biomarkers for KRAS mutation subtypes in adenocarcinoma and squamous cell NSCLC histologies. Frequency of the 10 most common co-occurring mutations including TP53, STK11, ATM, KEAP1, CDKN2A, U2AF1, BRAF, NFE3L2, RAF1 and EGFR are displayed for each KRAS mutation subtype in adenocarcinoma and squamous cell NSCLC cohorts.

Year:

2024

Supplemental Figure 1. Key Biomarkers for KRAS mutation subtypes in adenocarcinoma and squamous cell NSCLC histologies. Frequency of the 10 most common co-occurring mutations including TP53, STK11, ATM, KEAP1, CDKN2A, U2AF1, BRAF, NFE3L2, RAF1 and EGFR are displayed for each KRAS mutation subtype in adenocarcinoma and squamous cell NSCLC cohorts.

Year:

2024

Supplemental Table 2. Immune checkpoint therapy associated markers among KRAS-mutated tumors (A), comparison of these markers between KRAS G12C and all other subtypes (B) and further comparison between G12C, G12A and G13D subtypes (C). * represents p or q values

Year:

2024

Supplemental Table 2. Immune checkpoint therapy associated markers among KRAS-mutated tumors (A), comparison of these markers between KRAS G12C and all other subtypes (B) and further comparison between G12C, G12A and G13D subtypes (C). * represents p or q values

Year:

2024

Supplemental Figure 2 . Differences in co-mutations and immune markers between patients with KRAS mutated (KRAS MT) NSCLC with or without an ATM mutation (ATM MT; A) and between patients with KRAS mutated (KRAS MT) NSCLC with or without a U2AF1 co-mutation (U2AF1 MT; B). (A) Frequency of the 10 most common co-occurring mutations as well as TMB high in patients with tumors harboring KRAS mutations with or without an ATM mutation. (B) Fequency of the 10 most common co-occurring mutation in patients with tumors harboring both KRAS mutations with or without U2AF1 mutations.

Year:

2024

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS -mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS -mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.

Year:

2024

Supplemental Figure 2 . Differences in co-mutations and immune markers between patients with KRAS mutated (KRAS MT) NSCLC with or without an ATM mutation (ATM MT; A) and between patients with KRAS mutated (KRAS MT) NSCLC with or without a U2AF1 co-mutation (U2AF1 MT; B). (A) Frequency of the 10 most common co-occurring mutations as well as TMB high in patients with tumors harboring KRAS mutations with or without an ATM mutation. (B) Fequency of the 10 most common co-occurring mutation in patients with tumors harboring both KRAS mutations with or without U2AF1 mutations.

Year:

2024

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS -mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS -mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.

Year:

2024

Collaborators (7)

Jorge Nieva

Professor of Clinical Medicine

University of Southern California

UNITED STATES
View details

Hirva Mamdani

Karmanos Cancer Institute

UNITED STATES
View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES
View details

Misako Nagasaka

University of California Irvine School of Medicine

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Chul Kim

Georgetown University

UNITED STATES
View details

Luis E. Raez

-

UNITED STATES
View details